A multicentre phase II study of risk evaluation in gastrointestinal stromal tumour (GIST) with selective therapy escalation for response.
Purpose of the Study
The REGISTER study aimed to evaluate the time to ultimate disease progression in patients with exon 9/wild type (WT) gastrointestinal stromal tumours (GIST) who were not suitable for surgery using a risk -stratification and sequential dose escalation strategy of imatinib followed by nilotinib, in comparison with historical controls.
DETAILED INFORMATION AVAILABLE
Available online at the Australian New Zealand Clinical Trial Registry (ANZCTR), please click here
Conference Presentation Reference
- Kumar SS, Kirkpatrick CM, Mann KP, Ray JE, Graham GG, Williams KM, Day RO, Desai J. Imatinib PKPD relationship: Results from an ongoing study. Australasian Society of Clinical and Experimental Pharmacology and Toxicology (ASCEPT) Annual Scientific Meeting; 1–4 Dec 2013; Melbourne.
- Desai J, Goldstein D, McArthur G, Hicks R, Fox S, Kotasek D, Kang YK, Bracken K, Gebski V, Zalcberg J; on behalf of the Australasian Gastro-Intestinal Trials Group. The REGISTER study: a multicentre phase II study of risk evaluation in gastrointestinal stromal tumor with selective therapy escalation for response. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago.
- Desai J, Kang YK, Kotasek D, Robinson B, McArthur GA, Hicks R, Fox SB, Gebski V, Mann B, Gill RK, Wollin B, Zalcberg JR, Goldstein D. REGISTER: a multicentre phase II study of risk evaluation in gastrointestinal stromal tumor with selective therapy escalation for response. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.
To evaluate a risk-modified dose-escalation strategy for patients with advanced GIST based on their underlying KIT mutation status (high-risk: exon 9 / wild type (WT) vs low-risk: exon 11).
Dr Jayesh Desai